M
41.75
-0.25 (-0.60%)
| Previous Close | 42.00 |
| Open | 42.20 |
| Volume | 3,279,647 |
| Avg. Volume (3M) | 7,642,422 |
| Market Cap | 16,066,150,400 |
| Price / Sales | 3.20 |
| Price / Book | 1.36 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -43.77% |
| Operating Margin (TTM) | -3.76% |
| Diluted EPS (TTM) | -5.81 |
| Quarterly Revenue Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 11.36% |
| Current Ratio (MRQ) | 4.39 |
| Operating Cash Flow (TTM) | -3.21 B |
| Levered Free Cash Flow (TTM) | -3.34 B |
| Return on Assets (TTM) | -9.55% |
| Return on Equity (TTM) | -17.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Moderna, Inc. | Bullish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.80 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 9.52% |
| % Held by Institutions | 71.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Theleme Partners Llp | 30 Sep 2024 | 7,226,861 |
| Flagship Pioneering Inc. | 30 Sep 2024 | 4,632,149 |
| Banque Pictet & Cie Sa | 30 Sep 2024 | 3,155,399 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 111.00 (Barclays, 165.87%) | Buy |
| Median | 55.00 (31.74%) | |
| Low | 38.00 (Morgan Stanley, -8.98%) | Hold |
| Average | 61.44 (47.16%) | |
| Total | 4 Buy, 2 Hold, 3 Sell | |
| Avg. Price @ Call | 42.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 15 Jan 2025 | 38.00 (-8.98%) | Hold | 34.46 |
| UBS | 08 Jan 2025 | 96.00 (129.94%) | Buy | 43.17 |
| 24 Oct 2024 | 108.00 (158.68%) | Buy | 52.80 | |
| B of A Securities | 10 Dec 2024 | 41.00 (-1.80%) | Sell | 41.51 |
| JP Morgan | 26 Nov 2024 | 45.00 (7.78%) | Sell | 42.05 |
| 04 Nov 2024 | 59.00 (41.32%) | Sell | 53.54 | |
| HSBC | 18 Nov 2024 | 58.00 (38.92%) | Buy | 39.51 |
| Piper Sandler | 18 Nov 2024 | 69.00 (65.27%) | Buy | 39.51 |
| Wolfe Research | 15 Nov 2024 | 40.00 (-4.19%) | Sell | 36.85 |
| Barclays | 08 Nov 2024 | 111.00 (165.87%) | Buy | 46.83 |
| Bernstein | 17 Oct 2024 | 55.00 (31.74%) | Hold | 54.82 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOCK JAMES M | - | 42.18 | -780 | -32,900 |
| Aggregate Net Quantity | -780 | |||
| Aggregate Net Value ($) | -32,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 42.18 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOCK JAMES M | Officer | 03 Jan 2025 | Disposed (-) | 780 | 42.18 | 32,900 |
| MOCK JAMES M | Officer | 03 Jan 2025 | Option execute | 1,453 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |